NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NEOGENOMICS, INC. reports amended beneficial ownership by Greenhouse Funds LLLP, Greenhouse GP LLC and Joseph Milano as joint filers. Each reporting person is shown with 9,215,903 shares of Common Stock, representing 7.1% of the class. The filing lists 8,318,358 shares with shared voting power and 9,215,903 shares with shared dispositive power.
The report states the shares are owned by advisory clients of Greenhouse Funds LLLP and includes a joint filing agreement and a control-person identification exhibit. Signatures by Joseph Milano dated 05/15/2026 appear on the amendment.
NeoGenomics, Inc. filing amends a prior Schedule 13G to report that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each disclose shared voting and shared dispositive power over 2,222,757 shares of NeoGenomics common stock, representing 1.7% of the class. The filing is accompanied by a Joint Filing Agreement dated May 12, 2026 and clarifies that the shares are held by entities over which the filing parties have voting or investment discretion.
NeoGenomics EVP and General Counsel Alicia C. Olivo reported routine equity compensation activity. On May 11, 2026, 3,944 shares of common stock were acquired through the vesting and conversion of restricted stock units, while 2,559 shares were withheld to cover tax obligations.
Following these transactions, she holds 96,126 shares of common stock directly. The filing also shows substantial remaining equity incentives, including multiple tranches of restricted stock units, performance stock units and stock options with exercise prices ranging from $9.45 to $48.99 per share and expirations extending to 2036.
NeoGenomics Inc. President & Chief Operating Officer Warren Stone reported a routine equity compensation event. On May 11, 2026, he exercised 5,830 restricted stock units into an equal number of shares of common stock. Of these, 3,783 shares of common stock were withheld to satisfy tax obligations through a share delivery mechanism.
Following these transactions, Mr. Stone directly holds 164,032 shares of NeoGenomics common stock. The filing also lists substantial existing awards of restricted stock units, performance stock units, and stock options with various vesting schedules and premium exercise prices, reflecting a compensation package tied to service, share-price growth and revenue growth goals.
Neogenomics, Inc. amendment filing reports that First Light Asset Management, LLC beneficially owns 13,631,016 shares (10.47%) and Mathew P. Arens beneficially owns 14,093,416 shares (10.82%). The filing is a joint Schedule 13G/A stating shared voting and dispositive power for the Manager and Mr. Arens.
NeoGenomics Chief Accounting Officer Greg D. Aunan reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 2, 2026, he exercised 5,372 restricted stock units into common stock and, in connection with vesting, surrendered shares to the company to satisfy tax obligations. The filings show 2,246 common shares disposed through issuer withholding across May 1 and May 2, 2026, and he now directly holds 25,153 shares of common stock. He also retains multiple unexercised stock option and RSU awards with exercise prices between $9.83 and $14.62 per share and expirations extending to 2036.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported updated equity holdings in the company. The filing shows a disposition of 1,042 shares of common stock on May 1, 2026 as a tax-withholding transaction, leaving her with 92,182 common shares held directly.
Alongside these shares, she holds a range of equity awards in the form of restricted stock units, performance stock units and stock options tied to NeoGenomics common stock, with various exercise prices and expiration dates, reflecting a substantial, long-term incentive position rather than open-market trading activity.
NeoGenomics, Inc. President & Chief Operating Officer Warren Stone reported routine equity compensation activity involving restricted stock units and stock options. On May 2, 2026, he exercised awards to acquire 5,969 shares of common stock, with 2,349 shares withheld by the company to cover tax obligations related to the RSU release.
Following these transactions, Stone holds 161,985 shares of common stock directly, along with a substantial remaining equity incentive position, including 253,378 stock options at an exercise price of $10.81 and 166,113 stock options at $11.21, plus significant restricted and performance stock units that vest over future years.
NeoGenomics Inc Schedule 13G shows Vanguard Capital Management beneficially owns 6,610,272 shares of Common Stock, representing 5.09% of the class.
The filing lists sole dispositive power over 6,610,272 shares and sole voting power over 954,449 shares, and is signed on 04/30/2026.
Vanguard Portfolio Management reports beneficial ownership of 7,677,794 shares of NeoGenomics Inc. under Schedule 13G, representing 5.91% of the outstanding common stock as reported. The filing shows Vanguard has 55,607 shares with sole voting power and 7,677,794 shares with sole dispositive power.
The disclosure lists the issuer CUSIP 64049M209 and identifies Vanguard affiliates included in the reporting group. Signature is by Ashley Grim, Head of Global Fund Administration, dated 04/29/2026.